The Michigan Antibody Technology Center (MATC) consists of two individual cores: the Monoclonal Antibody Technology Core at Van Andel Research Institute in Grand Rapids and the Hybridoma Core at the University of Michigan in Ann Arbor. The MATC has extensive capabilities in generation, characterization, scale-up production and purification of a variety of mAbs using comprehensive cutting-edge technologies.

Our goals are to provide state-of-the-art antibody technologies and services to research scientists; generate, characterize, produce and purify a wide variety of monoclonal antibodies; make human antibody fragments for clinical diagnostic/therapeutic applications; and advance bio-medical research and development.

• Antigen preperation and animal immunization.
• Conventional techniques of hybridoma production.
• Hybridoma expansion and subcloning.
• Cryopreservation of hybridomas secreting mAbs.
• Monoclonal antibody isotyping.
• ELISIA screening of hybridoma supernatants and mAb characterization.
• Production of mAbs - high density cell culture techniques.
• Purification of mAbs - FPLC affinity columns.
• Generation of bi-specific mAbs by secandary infusion.

MATC Website

CONTACT:

Mr. Tom DeKoning, Marketing Manager, CTA Corp CTACorp@vai.org

Brian Cao, M.D., Senior Scientific Investigator, MATC brian.cao@vai.org